Clinical trials: High Risk Localised Prostate Carcinoma
Prostate Cancer
A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone
This study investigates neoadjuvant TAK-700 orteronel for 6 months prior to prostatectomy. The three year biochemical free survival is the primary endpoint.
- Trial name
- NEPTUNE (NCT03211052)
- Testing
- TAK-700 and LHRH agonist, prostatectomy
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Centre of Experimental Medicine
Prostate Cancer
Focal Therapy for Localized Prostate Cancer
This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.
- Trial name
- NCT06270043
- Testing
- Focal Therapy
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Prostate Cancer
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
This is a two-Parallel cohort, prospective study, aimed to explore Efficacy and safety of neoadjuvant Darolutamide with or without ADT in high-risk/very high-risk localized-stage prostate cancer.
- Trial name
- ANDARP (NCT07476677)
- Testing
- Darolutamide, Darolutamide combined with ADT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body…
- Conditions
- Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04947254
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Apalutamide
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer.
- Trial name
- NCT05826470
- Testing
- TRANBERG®|Thermal Therapy System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Genesis Research LLC
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasms
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after…
- Trial name
- ADAM (NCT04295447)
- Testing
- Standard of care, Apalutamide 60Mg Tab
- Where
- 21 sites in Austria, Germany
- Volunteers
- 190 people
- Sponsor
- Universität Münster
Prostate Cancer
Experiences With HDR-brachytherapy in Norway
There are 3 articles that will be written about the experience with HDR-brachytherapy (HDR-BT) in patients with high-risk prostate cancer in Norway as part of a doctorial thesis-project.
- Trial name
- NCT03162523
- Testing
- High-Dose Rate Brachytherapy
- Where
- Norway
- Volunteers
- 325 people
- Sponsor
- Oslo University Hospital
Prostate Cancer
Circulating Tumor DNA in High Risk Localized Prostate Cancer
This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.
- Trial name
- NCT07222436
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pittsburgh
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH…
- Trial name
- PEGASUS (NCT02799706)
- Testing
- Degarelix, approved GnRH agonist, Radiotherapy
- Where
- 39 sites in Belgium, Denmark and 6 more
- Volunteers
- 885 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Localized Prostate Cancer
Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device
Focal treatment of localized prostate cancer aims to destroy the cancerous foci without damaging surrounding tissues to avoid the side effects of radical treatments.
- Trial name
- IDITOP-3 (NCT02662673)
- Testing
- Focal High Intensity Focused Ultrasound (HIFU) treatment
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer
Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer
This is an open-label randomized clinical study comparing primary prostate cryoablation alone (No-ADT group) with cryoablation plus short-term adjuvant androgen-deprivation therapy (Adj-ADT group) in the treatment of patients…
- Trial name
- NCT01398657
- Testing
- Adjuvant Androgen-Deprivation Therapy
- Where
- Taiwan
- Volunteers
- 182 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor…
- Trial name
- NCT00714753
- Testing
- brachytherapy, hypofractionated radiation therapy, image-guided radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Prostatic Diseases, Genital Neoplasms, Male
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery.
- Conditions
- Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT00672009
- Testing
- Ixabepilone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope
Prostate Cancer
The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Silibinin has demonstrated anti-cancer activity in the laboratory for several different cancer types, including prostate cancer. Silibinin was originally obtained from milk thistle.
- Trial name
- NCT00487721
- Testing
- Silibin-Phytosome
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals